Clinical trials: Peripheral Neuropathies
- Condition Peripheral Neuropathies
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Diabetic Peripheral Neuropathy
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP).
- Trial name
- NCT06074562
- Testing
- Mazisotine
- Where
- 70 sites in United States, Czechia and 3 more
- Volunteers
- 404 people
- Sponsor
- Eli Lilly and Company
Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Phase 3 Gene Therapy for Painful Diabetic Neuropathy
The purpose of this study is to determine the safety and efficacy of bilateral intramuscular injections of VM202 versus placebo in the treatment of painful diabetic peripheral neuropathy.
- Trial name
- NCT02427464
- Testing
- Engensis (VM202)
- Where
- 25 sites in United States
- Volunteers
- 507 people
- Sponsor
- Helixmith Co., Ltd.
Diabetic Peripheral Neuropathy
A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
To evaluate the durability of efficacy and long-term safety of intramuscular administration of Engensis or Placebo that was administered in the double-blind, randomized, VMDN-003-2 Placebo-controlled Phase 3 Study.
- Trial name
- REGAiN-1B (NCT04873232)
- Testing
- Engensis
- Where
- 16 sites in United States
- Volunteers
- 106 people
- Sponsor
- Helixmith Co., Ltd.
Painful Diabetic Peripheral Neuropathy
Gene Therapy for Painful Diabetic Neuropathy
The purpose of this open label, Phase I/II, dose-escalation, 3-cohort, multicenter, 12-month study, is to assess the safety and tolerability of injecting Engensis (VM202) in the leg muscle in patients with painful diabetic…
- Trial name
- NCT01002235
- Testing
- VM202
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Helixmith Co., Ltd.
Neuropathy, Diabetic, Neuropathy;Peripheral
Clinical Efficacy and Human Factors Validation Testing of the Erchonia EVRL for Providing Temporary Relief of Diabetic Peripheral Neuropathy Foot Pain
The purpose of this clinical study is to determine the effectiveness of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Company), in providing prescription home use application for temporary relief of diabetic…
- Conditions
- Neuropathy, Diabetic, Neuropathy;Peripheral, Neuropathy, Painful
- Trial name
- NCT05291975
- Testing
- Erchonia® EVRL™
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- Erchonia Corporation
Diabetic Peripheral Neuropathy
Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)
The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating Painful DPN.
- Trial name
- NCT05660538
- Testing
- Suzetrigine, Pregabalin
- Where
- 50 sites in United States
- Volunteers
- 194 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Diabetic Peripheral Neuropathy, Diabetes
Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
Evaluation of the efficacy of a low and high dose of LX9211 compared to placebo in reducing pain related to diabetic peripheral neuropathy (DPNP) over an 11 week assessment period.
- Trial name
- RELIEF-DPN 1 (NCT04455633)
- Testing
- LX9211
- Where
- 44 sites in United States
- Volunteers
- 319 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetic Peripheral Neuropathic Pain, Diabetic Peripheral Neuropathy
Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects with Diabetic Peripheral Neuropathic Pain.
- Trial name
- NCT04688671
- Testing
- ETX-018810
- Where
- 22 sites in United States
- Volunteers
- 167 people
- Sponsor
- Eliem Therapeutics (UK) Ltd.
Painful Diabetic Peripheral Neuropathy
Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy
This is a randomized, double-blind, 2-arm, parallel group study of up to 274 evaluable patients designed to evaluate the safety and efficacy of the histone deacetylase 6 (HDAC6) inhibitor ricolinostat for painful DPN.
- Trial name
- NCT03176472
- Testing
- ricolinostat
- Where
- 35 sites in United States
- Volunteers
- 282 people
- Sponsor
- Regenacy Pharmaceuticals LLC
Pain, Peripheral Neuropathy
A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia
The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in relieving peripheral neuropathic pain associated with allodynia.
- Trial name
- NCT00710554
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 246 people
- Sponsor
- Jazz Pharmaceuticals
Pain, Peripheral Neuropathy
A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.
The purpose of this study is to assess the safety and tolerability of long term therapy with Sativex® in relieving neuropathic pain.
- Trial name
- NCT00713323
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 380 people
- Sponsor
- Jazz Pharmaceuticals
Pain, Peripheral Neuropathy
A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain
The purpose of this study is to assess the maintenance of effect after long-term treatment of Sativex® in subjects with neuropathic pain.
- Trial name
- NCT00713817
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Jazz Pharmaceuticals
Pain, Peripheral Neuropathy
A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.
The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in relieving peripheral neuropathic pain associated with allodynia.
- Trial name
- NCT00711880
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 125 people
- Sponsor
- Jazz Pharmaceuticals
Diabetic Peripheral Neuropathy
An Evaluation of the Effect of Low Level Laser Therapy on Diabetic Peripheral Neuropathy Pain
The purpose of this study is to determine whether low level laser therapy is effective in the reduction of foot pain associated with diabetic peripheral neuropathy.
- Trial name
- NCT04006392
- Testing
- Erchonia FX-635
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Erchonia Corporation
Sensory Peripheral Neuropathy, Balance; Distorted
walk2Wellness: Long-term Effects of Walkasins® Wearable Sensory Prosthesis
The purpose of this study is to investigate the long-term effects of Walkasins® use on clinical and subject-reported outcomes of balance and gait function, quality of life, physical activity/participation, pain, and medication…
- Conditions
- Sensory Peripheral Neuropathy, Balance; Distorted, Sensation Disorders
- Trial name
- NCT03538756
- Testing
- Walkasins
- Where
- 5 sites in United States
- Volunteers
- 69 people
- Sponsor
- RxFunction Inc.
Diabetic Peripheral Neuropathy
Study of Low Level Laser Therapy to Treat Diabetic Peripheral Neuropathy Foot Pain
The purpose of this study is to determine whether low level laser therapy is effective in the reduction of foot pain associated with diabetic peripheral neuropathy.
- Trial name
- NCT02461225
- Testing
- Erchonia® FX-635™
- Where
- 2 sites in United States, Ireland
- Volunteers
- 30 people
- Sponsor
- Erchonia Corporation
Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy
Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer
This study is to evaluate PledOx for prevention of chronic chemotherapy induced peripheral neuropathy induced by oxaliplatin in patients with Stage III or high-risk Stage II colorectal cancer (CRC).
- Trial name
- POLAR-A (NCT04034355)
- Testing
- Calmangafodipir (5 µmol/kg)
- Where
- 65 sites in Belgium, Czechia and 8 more
- Volunteers
- 301 people
- Sponsor
- Egetis Therapeutics AB (publ)
Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy
Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)
This study evaluates the investigational drug PledOx in the prevention of chronic chemotherapy induced peripheral neuropathy (CIPN) induced by the drug oxaliplatin.
- Trial name
- POLAR-M (NCT03654729)
- Testing
- Calmangafodipir (2 µmol/kg), Calmangafodipir (5 µmol/kg)
- Where
- 98 sites in United States, Belgium and 11 more
- Volunteers
- 291 people
- Sponsor
- Egetis Therapeutics AB (publ)
Neuropathic Pain, Diabetic Peripheral Neuropathy (DPN)
Oral LAT8881 in Neuropathic Pain
This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain.
- Conditions
- Neuropathic Pain, Diabetic Peripheral Neuropathy (DPN), Post Herpetic Neuralgia (PHN)
- Trial name
- NCT03865953
- Testing
- LAT8881
- Where
- 6 sites in Australia, United Kingdom
- Volunteers
- 53 people
- Sponsor
- Lateral Pharma Pty Ltd
Diabetic Peripheral Neuropathy
A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy
The purpose of this study is to determine the effectiveness and safety of the investigational drug, tanezumab, in adult patients with painful diabetic peripheral neuropathy.
- Trial name
- NCT01087203
- Testing
- Tanezumab
- Where
- 48 sites in United States
- Volunteers
- 73 people
- Sponsor
- Pfizer